Monographie - Telavancin hydrochloride

Viimeisin päivitys :
19/11/2024

Telavancin hydrochloride

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Vibativ

Iso-Britannia, Kanada, Yhdysvallat

Viitteet : Telavancin hydrochloride

	tyyppi	julkaisu
2006	Lehti	Gu Z, Wong A, Raquinio E, Nguyen A. Stability of Reconstituted Telavancin Drug Product in Frozen Intravenous Bags. Hosp Pharm 2015 ; 50, 7: 609-614.
3254	Lehti	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3260	Laboratorio	Telavancin (Vibativ®) - Summary of Products characteristics Astellas Pharma Europe 2011
3327	Lehti	LaPlante K.L, Woodmansee S, Mermel L.A. Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. Am J Health-Syst Pharm 2012 ; 69:1405-1409
3835	Lehti	Sand P, Aladeen T, Kirkegaard P, LaChance D, Slover C. Chemical Stability of Telavancin in Elastomeric Pumps. Current Ther Res 2015 ; 77: 99-104.
3839	Lehti	Gu Z, Parra C, Wong A, Nguyen A, Cheung R, Catalano T. Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions. Current Ther Res 2015 ; 77: 105-110.

Mentions Légales